leadf
logo-loader
viewLexaGene Holdings Inc.

Full interview: LexaGene teams up with Assurance Scientific to beta test its diagnostic in humans

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) CEO Dr Jack Regan notes that the firm is teaming up with Assurance Scientific Laboratories (ASL) to test its rapid pathogen detection technology on human urine samples. Dr Regan says ASL has the ability to bring LexaGene's diagnostic in-house, validate it, and begin using it for clinical diagnostic.

Quick facts: LexaGene Holdings Inc.

Price: 0.85 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $96.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of LexaGene Holdings Inc. named herein, including the promotion by the Company of LexaGene Holdings Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

LexaGene hires two salespeople to tackle diagnostic and vet market with new...

LexaGene (CVE: LXG-OTCQB: LXXGF) CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver with news the company has made two key sales hires as they look to begin to roll out their genetic analyzers for rapid pathogen detection called MiQLab. Regan says they are hiring in the...

on 14/7/20

2 min read